text:
|31st week of 2011 patent applcation highlights part 43
|Patent application number
|DIAGNOSTICS IN A MONOPLEX/MULTIPLEX FORMAT - The present invention relates to a method of detecting and/or quantifying a target molecule from a sample obtained from a subject wherein the method comprises: (i) incubating a fusion protein or conjugate comprising a Ter binding polypeptide fused to at least one anti-target molecule or fragment thereof with a partially double-stranded oligonucleotide for a time and under conditions sufficient to bind to said Ter binding polypeptide thereby producing a complex; (ii) incubating said complex in the presence of said sample comprising said target molecule for a time and under conditions sufficient for said anti-target molecule to bind to said target molecule thereby producing a target-bound complex; (iii) incubating said target-bound complex in the presence of at least one immobilised molecule wherein said immobilised molecule has an affinity to said target molecule; (iv) incubating said immobilised molecule for a time and under conditions sufficient to bind to said target molecule thus immobilising said target molecule; and (v) detecting and/or quantifying said target molecule.
|METHODS FOR DETECTING DRUG-RESISTANT MICROBES - The present invention provides methods and oligonucleotides for detecting drug-resistant microbes, such as vancomycin resistant
|NUCLEIC ACID PROBE SET AND METHOD OF USING THE SAME - A nucleic acid probe set includes (A) a fluorescent probe and (B) a binding probe. The fluorescent probe (A) is formed of an oligonucleotide including (a) a nucleotide labeled with a fluorescent substance. The binding probe (B) is formed of an oligonucleotide having (b
|METHOD OF SCREENING FOR NOVEL EXON 1 MUTATIONS IN MECP2 ASSOCIATED WITH CLASSICAL RETT SYNDROME - Recently, a new MECP2 isoform, which has an alternative N-terminus, transcribed from exon 1, was described. Since the incorporation of exon 1 into standard sequencing protocol for Rett syndrome, few patients with exon 1 mutations have been described and several groups have concluded that exon 1 mutations are a rare cause of Rett syndrome. The present invention provides an improved method of diagnosing Rett Syndrome by identifying two different mutations in exon 1 of the MECP2 gene, the first of which results in a switch from alanine to valine at the beginning of a polyalanine stretch, and the second of which results in a disruption of the ATG initiation codon of exon 1. Patients having either such mutation fit the clinical criteria for classic Rett syndrome, and further support previous reports that exon 1 mutations may be associated with a severe phenotype.
|Methods for determining likelihood of longevity and of developing an age-related disease - The present invention provides a method for identifying a subject's likelihood of achieving longevity or of developing an age-related disease, the method for identifying a subject's likelihood of achieving longevity or of developing an age-related disease comprising detecting at least one specified single nucleotide polymorphisms or genotype at a single nucleotide polymorphism or combination of a genotype at a first single nucleotide polymorphism and a genotype at a second single nucleotide polymorphism in a sample of the subject's DNA and, wherein the detection of at least one single nucleotide polymorphisms or genotype at a single nucleotide polymorphism or combination of a genotype at a first single nucleotide polymorphism and a genotype at a second single nucleotide polymorphism identifies the subject's as likely achieving longevity or of developing an age-related disease.
|METHODS OF AIDING IN THE DIAGNOSIS OF PROSTATE CANCER - The current invention provides a method for aiding in the assessment of prostate cancer (including metastatic prostate cancer) and/or benign prostate hyperplasia in a patient, wherein the method comprises the step of determining the level of Glycine N-methyltransferase (GNMT) nucleic acid and/or protein in a sample from the patient. The invention also provides compounds that target Glycine N-methyltransferase (GNMT) protein and/or nucleic acid for use in treating prostate cancer. Also provided are screening methods for selecting a compound considered to be useful in treating prostate cancer, comprising the steps of determining the ability of a test compound to reduce GNMT activity and selecting a compound that reduces GNMT activity. The invention also provides methods for aiding in the diagnosis of prostate cancer in a patient comprising obtaining a sample from the patient and assessing said sample for a marker of GNMT activity.
|Circulating Tumor and Tumor Stem Cell Detection Using Genomic Specific Probes - The present invention comprises a method of detecting circular tumor cells and methods of detecting, evaluating, or staging cancer in a patient, as well as a method of monitoring treatment of cancer in a patient using the claimed method. The method comprises contacting a sample with a CD45 binding agent; selecting the cells based on positive or negative CD45 staining; contacting the selected cells with a labeled nucleic acid probe, and detecting hybridized cells by fluorescence in situ hybridization; and analyzing a signal produced by the labels on the hybridized cells to detect the CTCs. In other embodiments, the method provides for directed to a method of determining the level of CTCs in a sample having blood cells from a patient by contacting a sample having blood cells from a patient, wherein the sample has not been pre-sorted into CD45-positive and CD45-negative cells.
|NUCLEOSIDE TRIPHOSPHATE DERIVATIVE, NUCLEIC ACID PROBE, MULTILABELED NUCLEIC ACID PROBE, METHOD FOR PRODUCTION OF MULTILABELED NUCLEIC ACID PROBE, AND METHOD FOR DETECTION OF TARGET NUCLEIC ACID - A novel nucleoside triphosphate derivative, a nucleic acid probe, and a multilabeled nucleic acid probe that can detect a target nucleic acid conveniently and with high sensitivity, as well as a method for producing the multilabeled nucleic acid probe, and a method for detecting a target nucleic acid using the multilabeled nucleic acid probe or the nucleic acid probe. A target nucleic acid can be detected conveniently and with high sensitivity by using a transglutaminase (TGase), and by using a multilabeled nucleic acid probe in which a plurality of labeling portions have been introduced in advance by covalent binding, or by introducing a plurality of labeling portions by covalent binding into a nucleic acid probe that has been hybridized with the target nucleic acid.
|DIAGNOSTIC METHODS INVOLVING DETERMINING GENE COPY NUMBERS AND SNPs IN THE FcyRll/FcyRlll GENE CLUSTER, AND PROBES FOR USE IN SUCH METHODS TO DETECT SUSCEPTIBILITY TO AND TREATMENT EFFICACY IN AUTOIMMUNE DISEASES - The invention relates to diagnostic methods to predict whether a subject is predisposed for acquiring a disease or to predict the therapy responsiveness of an individual patient. Provided is a method for determining whether a subject is predisposed for developing an autoimmune disease, comprising determining in a sample isolated from said subject the amount of intact genes, or gene products thereof, of the FcγRII/FcγRIII gene cluster, said gene cluster comprising the FCGR2C, FCGR3A, FCGR2A and FCGR3B genes encoding an activating FcγR, and FCGR2B encoding an inhibitory FcγR; and correlating said amount to the amount observed in a healthy population. Also provided is a method to predict the responsiveness of a subject to therapy with intravenous immunoglobulin (IVIg) therapy or a monospecific biological, such as a humanized or human monoclonal antibody or a chimeric molecule, comprising the C-terminal Fc-tail of IgG.
|STOOL SAMPLE PREPARATION METHOD, SOLUTION FOR PREPARING STOOL SAMPLE AND STOOL COLLECTION KIT - The present invention relates to the providing of a method for preparing a stool sample that enables nucleic acids in a stool to be stably preserved without requiring a complex procedure, a stool sample preparation solution and stool collection kit used in that method, and a method for recovering and analyzing nucleic acids in a stool using a stool sample prepared according to the preparation method of the present invention, and a stool sample having superior preservation of nucleic acids contained in the stool sample is prepared by mixing a collected stool with the stool sample preparation solution having for an active ingredient thereof a water-soluble organic solvent containing an organic acid.
|METHOD FOR QUANTIFYING OR DETECTING DNA - The present invention relates to a method for quantifying or detecting DNA having a target DNA region, and so on.
|Method For Administering Anticoagulation Therapy - The present invention provides a method for use in treating a patient with an anticoagulant to optimize drug therapy and/or to prevent an adverse drug response. More particularly, the present invention relates to a method and system for use in treating a patient with Coumadin® or a substance containing warfarin. Methods of the present invention utilize variables that include the patient's CYP4F2 genotype.
|COMPOSITIONS FOR USE IN IDENTIFICATION OF FUNGI - The present invention relates generally to identification of fungi pathogens, and provides methods, compositions, systems and kits useful for this purpose when combined, for example, with molecular mass or base composition analysis.
|Methods For Preparing Sequencing Libraries - Improvements in chromatin immunoprecipitation-high throughput sequencing techniques has allowed the creation of chromatin maps from limited biological sample sizes that cannot be evaluated using conventional chromatin immunoprecipitation-sequencing protocols. For example, a modified universal primer is utilized that incorporates restriction enzymes into chromatin immunoprecipitation fragments before amplification. The improved method allows the sample sizes to be several orders of magnitude less than that required for standard ChIP-Seq techniques.
|Microfluidic Device and Methods of Using Same - A variety of elastomeric-based microfluidic devices and methods for using and manufacturing such devices are provided. Certain of the devices have arrays of reaction sites to facilitate high throughput analyses. Some devices also include reaction sites located at the end of blind channels at which reagents have been previously deposited during manufacture. The reagents become suspended once sample is introduced into the reaction site. The devices can be utilized with a variety of heating devices and thus can be used in a variety of analyses requiring temperature control, including thermocycling applications such as nucleic acid amplification reactions, genotyping and gene expression analyses.
|COMPOSITIONS AND METHODS FOR WHOLE TRANSCRIPTOME ANALYSIS - The present invention provides methods and compositions, including kits, for the generation of cDNA from mRNA with reduced ribosomal RNA representation.
|Methods of Diagnosing Rejection of a Kidney Allograft Using Genomic or Proteomic Expression Profiling - A method of determining the acute allograft rejection status of a subject, the method comprising the steps of: determining the nucleic acid expression profile of one or more than one nucleic acid markers, or one or more than one proteomic markers in a biological sample from the subject; comparing the expression profile of the one or more than one nucleic acid markers to a control profile; and determining whether the expression level of the one or more than one nucleic acid markers is increased relative to the control profile, wherein the increase of the one or more than one nucleic acid markers is indicative of the acute rejection status of the subject.
|STAT3 AND TYK2 AS DRUG TARGETS FOR NEURODEGENERATIVE DISEASES - The invention provides Stat3 and Tyk2 targets that have importance for diagnosis of neurode-generative diseases such as Alzheimer's disease. Stat3 and Tyk2 are also important as targets for drug development for neurodegenerative diseases.
|TOOLS FOR OBJECTIVELY DETERMINING SEVERITY OF SYSTEMIC SCLEROSIS - Methods are disclosed for the identification and use of biomarkers in order to objectively measure systemic sclerosis. The biomarker may be a single gene, or may be a combination of multiple genes. A preferred embodiment in which the biomarker is a four gene combination of two TGFβ regulated genes (COMP and THS1), and two IFN regulated genes (IFI44 and SIG1) is the best identified predictor of systemic sclerosis as measured by the modified Rodnan skin score.
|Method of Nucleic Acids Analysis by Real-time Polymerase Chain Reaction and Device for Performing the Same - The invention refers to molecular biology, medicine, biotechnology and is related to performance of Polymerase Chain Reaction and device for its implementation with real-time registration of reaction-product build-up. The task of the invention is solved as a result of using the method and device for its implementation for identification of nucleic acids by a real-time polymerase chain reaction including introduction of liquid samples containing nucleic acid into the reaction zones on the upper surface of the heat-conducting substrate of the microchip; isolation of the introduced samples from the atmosphere; contact of the nucleic acid of the sample with components of the polymerase chain reaction during thermocycling of the samples with heat removal through the outer surface of the microchip; fluorescent detection of the change of the quantity of the polymerase chain reaction products during thermocycling; identification of the quantity of the initial nucleic acid in the samples by the dynamic of growth of the fluorescent signal wherein the microchip used contains a heat-conducting substrate from a heat-conducting material with the thermal conductivity coefficient of more than 1 W/cm·K and the thermal diffusivity coefficient of more than 0.6 cm
|METHOD FOR DETERMINING DRUG RESISTANCE MUTATIONS IN ANY OF THE NON-STRUCTURAL PROTEIN REGIONS NS3 TO NS5B OF HEPATITIS C VIRUS (HCV) FOR GENOTYPES 1 TO 6 - The present invention relates to a method for determining drug resistance mutations in any of the non-structural protein regions NS3 to NS5B of Hepatitis C Virus (HCV) for genotypes 1 to 6, more in particular for subtype specific genotypes 1a, 1b, 2a, 2b, 3a, 4a and 4d.
|METHODS OF USING JAK3 GENETIC VARIANTS TO DIAGNOSE AND PREDICT CROHN'S DISEASE - The present invention relates to methods of diagnosing and diagnosing susceptibility to Crohn's Disease by determining the presence or absence of risk variants at the JAK3 locus. In one embodiment, the present invention provides a method of diagnosing susceptibility to Crohn's Disease by determining the presence of a risk variant at the JAK3 locus, where the risk variant is associated with positive expression of ASCA and/or anti-I2.
|SCREENING FOR MODULATORS OF CYP2B15 AND/OR GPD1 FOR THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the CYP2B15 and/or glycerol-3-phosphate dehydrogenase 1 (GPD1) proteins.
|COMPOSITIONS FOR USE IN IDENTIFICATION OF MEMBERS OF THE BACTERIAL GENUS MYCOPLASMA - The present invention relates generally to identification of members of the bacterial class
|GENES - The invention relates to mutations in B-Raf gene products. The mutations described are identified in human tumours of natural origin. These mutations are associated with cancerous phenotypes and can be used as a basis for the diagnosis of cancer, cancerous cells or a predisposition to cancer in human subjects, and the development of anti-cancer therapeutics.
|RIBOSWITCHES - The TPP riboswitch is a target for antibiotics, herbicides, algicides, fungicides and other utilities. The atomic structure of the binding pocket of the TPP riboswitch has been resolved. Compounds identified and optimized using this information can be used to stimulate, activate, inhibit and/or inactivate the TPP riboswitch.
|ANTIBODY COMPLEX, METHOD FOR DETECTING ANTIGEN, AND METHOD FOR PRODUCING ANITBODY COMPLEX - In order to improve the detection sensitivity of MUSTag, the present invention provides an antibody complex including a nucleic acid chain as a label, an antibody to specifically recognize the antigen and an adaptor moiety linking the nucleic acid chain and the antibody, wherein the adaptor moiety includes an immunoglobulin binding domain of Protein G, Protein A or Protein L for binding with the antibody, and the adaptor moiety and the antibody are chemically cross-linked to form a cross-linked antibody complex.
|Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors - The present invention provides protein and gene expression profiles indicative of whether a patient afflicted with non-small cell lung cancer is likely to be responsive to treatment with a therapeutic compound that is a EGFR-TK inhibitor. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and protein expression profiles, and assays for identifying the presence of a gene or protein expression profile in a patient sample.
|ASSAY FOR PATHOGENIC CONFORMERS - The invention provides methods for detecting the presence of a non-prion pathogenic conformer in a sample by contacting the sample suspected of containing a non-prion pathogenic conformer with a pathogenic conformer-specific binding reagent under conditions that allow the binding of the reagent to the pathogenic conformer, if present; and detecting the presence the pathogenic conformer, if any, in the sample by its binding to the reagent; where the pathogenic conformer-specific binding reagent is typically derived from a prion protein fragment and interacts preferentially with a pathogenic prion protein. Methods for diagnosis of conformational diseases are also provided.
|Methods for Cancer Diagnosis, Anti-Cancer Drug Screening, and Test of Drug Effectiveness on the Basis of Phoshorylation of Ras at Thr-144 and Thr-148 - Methods of diagnosing cancer and screening for an anti-cancer drug using Ras are provided. Ras has a very significant role as a prevalent proto-oncogene which has abnormalities in most forms of cancer, and thus the methods of diagnosing cancer and screening for an anti-cancer drug using Ras may be applied to various forms of cancer. The generation of various forms of cancer in the early stages may be determined by examining whether or not phosphorylation of Ras occurs at Thr-144 and Thr-148 sites, By such a mechanism, an anti-cancer drug having excellent anti-cancer effectiveness may be screened, or the effectiveness of the anti-cancer drug may be tested.
|METHODS FOR DETECTION AND DIAGNOSIS OF A BONE OR CARTILAGE DISORDER - The present invention is directed to methods for the detection and diagnosis of bone and/or cartilage disorders, wherein the level of expression of a polypeptide in a test sample is measured by contacting the test sample with an antibody that specifically binds to said polypeptide and measuring the binding of said antibody to said test sample.
|METHOD AND DEVICE FOR PRODUCING METAL-CONTAINING ORGANIC COMPOUNDS - The invention relates to a method and to a device for producing conjugates comprising or consisting of a metallic nanoparticulate component and an organic component. Said method enables activated or reactive nanoparticles containing metal to be produced by irradiating a metal body with a laser beam and prevents the modification and damage of organic components of said conjugates by laser irradiation. Said nanoparticulate metallic component comprises plasmon resonant metal. According to the invention, the claimed method of production enables particles having a metal centre and a metal-oxide covering to be produced, in particular when using a carrier fluid containing oxygen, e.g. alcohol or water.
|MONOCLONAL ANTIBODY STRO-4 - The present invention relates to a monoclonal antibody designated STRO-4 which specifically binds human and ovine HSP-90beta and its use for enriching multipotential cells such a mesenchymal precursor cells (MPCs).
|RECOMBINANT CELLS AND PLANTS FOR SYNTHESIS OF VERY LONG CHAINS FATTY ACID (VLCFA) - The present disclosure is relative to a method for the production of Very-Long-Chain Fatty Acids (VLCFA) into a plant cell, including culturing a recombinant plant cell in an appropriate medium, wherein said plant cell is transformed with an heterologous gene encoding for an hydroxyacyl-CoA dehydratase. The disclosure is also relative to a method for producing vegetable oil including high levels of VLCFA.
|Protein Biomarkers and Methods for Diagnosing Kawasaki Disease - A method, kit and device for diagnosing Kawasaki Disease are provided. The invention provides detecting an expression level of at least two Kawasaki Disease diagnostic biomarkers in a biological sample from a patient with a capture agent and diagnosing the patient as having Kawasaki Disease when the expression levels of the at least two diagnostic biomarkers in the patient biological sample are higher than the normal expression levels of the same biomarkers in a biological sample from a control subject. The first Kawasaki Disease diagnostic biomarker disclosed in the present invention is a cardiomyocyte biomarker, and the second Kawasaki Disease diagnostic biomarker is an inflammatory biomarker. The invention further provides detecting an expression level of a third biomarker, interferon type-I biomarker, in the patient biological sample with a capture agent and diagnosing the patient as having Kawasaki Disease when the expression level of interferon type-I biomarker is lower than the expression level in a control subject.
|AUTOANTIBODIES FOR PROTEIN ANTIGENS AS MARKERS FOR CANCER OF GINGIVO-BUCCAL COMPLEX - The present invention relates to identification of a set of proteins, which elicit an autoantibody response in patients with cancer of gingivo-buccal complex. Systematic comparisons of serum samples from clinically normal individuals and from patients with cancer of gingivo-buccal complex has revealed significant differences in the presence of autoantibodies in sera against cellular antigens present in a cancer cell line. The autoantibody response to a single or combination of these protein antigens serves as a novel marker and can be utilized for screening, early detection, prognosis, and potential target for therapy. The invention also provides for the use of the identified protein antigens in immunoassays designed to detect the presence of serum antibodies to the specific protein antigens in sera from individuals that harbor such antibodies. The invention also relates to the use of the identified antigens as immunogens for stimulation of an immune response in patients expressing such protein antigens. The invention is demonstrated by way of example in which elevated levels of circulating antibodies reactive against tumor specific antigens were identified in sera derived from patients with cancer of gingivo-buccal complex. The utility of identified antigens for early detection is assessed by analysis of sera from patients with leukoplakia of gingivo-buccal complex.
|CYR61 AS A BIOMARKER FOR DIAGNOSIS AND PROGNOSIS OF CANCERS OF EPITHELIAL ORIGIN - Urinary Cyr61 protein levels are up regulated in patients that have cancers of epithelial origin, i.e. breast cancer and ovarian cancer. Accordingly, the present invention is directed to methods for prognostic evaluation, and diagnosis of cancers of epithelial origin. Further, the amount of Cyr61 protein detected in a urine sample correlates with disease status such that Cyr61 levels can be used to predict the presence of, as well as the metastatic potential of cancer. Thus, measuring the level of Cyr61 in urine provides a quick, easy, and safe screen that can be used to both diagnose and prognose cancer in a patient.
|CENTRIFUGAL MICRO-FLUIDIC DEVICE AND METHOD FOR DETECTING ANALYTES FROM LIQUID SPECIMEN - A centrifugal micro-fluidic device detecting analytes in a liquid specimen and a method of detection of analytes from a liquid specimen using the micro-fluidic device are provided. Reaction efficiency is increased using a repetitive flow of the liquid specimen induced by an alternating combination of capillary force and centrifugal force, thereby enhancing detection sensitivity.
|PHOTOLUMINESCENT MATERIALS FOR MULTIPHOTON IMAGING - Disclosed are nano-sized materials that can exhibit luminescence in a multi-photon imaging technique. The materials include a nano-sized particle or a carbon nanotube and a passivation agent bound to the surface of the nanoparticle or nanotube. The passivation agent can be, for instance, a polymeric material. The passivation agent can also be derivatized for particular applications. For example, the luminescent materials can be derivatized to recognize and bind to a target material, for instance a biologically active material, a pollutant, or a surface receptor on a tissue or cell surface, such as in a tagging or staining protocol. The materials exhibit strong luminescence with multi-photon excitation in the near infrared.
|High Throughput Cell-Based Assays, Methods of Use and Kits - In the present invention cells are placed in a multiwell plate and grown. When the assay is to be performed, one uses gravity to wash away any unbound ligands rather than vacuum or centrifugation. The cells are then examined to detect the bound ligand. To perform the washing step(s) the plate is placed into a carrier plate having open wells in register with the wells of the filter plate or one may use a wicking device or an underdrain attached to the bottom of the filter plate. Sufficient wash liquid is added to allow for filtration by the effect of gravity to occur. Cells are retained within the wells at a rate of 4 times that of other rapid methods.
|NON-SPECIFIC REACTION INHIBITOR - Disclosed is a non-specific reaction inhibitor for use in an immunological measurement, comprising a complex of an antibody or a fragment of the antibody capable of specifically binding to a non-specific reaction factor, and a polymer. The non-specific reaction inhibitor can inhibit a non-specific reaction which may interfere with the accurate detection or quantification of a trace substance in an immunological measurement method.
|Immunoassay - The invention provides a highly sensitive immunoassay for detection of a biological species. The immunoassay comprises exposing an electrode to an analyte liquid putatively containing the biological species so as to couple the biological species, if present in the analyte liquid, to a binding antibody on the electrode. The electrode comprises a binding antibody and an anchor group, each being coupled to an electrically conductive substrate, said binding antibody being capable of binding to the biological species and said anchor group being capable of binding to a redox polymer. The electrode is then exposed to an antibody-enzyme liquid comprising an antibody-enzyme species, said antibody-enzyme species comprising a detection antibody capable of binding to the biological species, said detection antibody being coupled to a redox enzyme, whereby, if the analyte liquid comprises the biological species, the redox enzyme couples to the electrode by means of the coupling of both the detection antibody and the binding antibody to the biological species. The electrode is then exposed to a polymer solution comprising the redox polymer and to an enzyme substrate, whereby if the redox enzyme is coupled to the anchor group on the electrode the redox polymer is reduced and couples to the anchor group on the electrode. A voltage is then applied between the electrode and a reference electrode and the electrode is exposed to an oxidisable species, whereby a magnitude of an electric current between said electrode and a reference electrode is indicative of the presence or absence of the biological species.
|PROCESS FOR THE MEASUREMENT OF THE POTENCY OF GLATIRAMER ACETATE - The subject invention provides a process for measuring the relative potency of a test batch of glatiramer acetate. In addition, the subject invention provides a process for preparing a batch of glatiramer acetate as acceptable for pharmaceutical use.
|Goodpasture Antigen Binding Protein and its Detection - The present invention provides native Goodpasture antigen binding protein isoforms, monoclonal antibodies directed against such proteins, and methods for their use.
|METHOD FOR EVALUATING SPECIFIC INCORPORATION OF D-GLUCOSE INTO CELLS - An object of the present invention is to provide a method for accurately evaluating the specific incorporation of D-glucose into cells. The present invention as a means for achieving the object is characterized by comprising contacting a D-glucose derivative that has a fluorescent chromophore in the molecule and is specifically incorporated into cells and an L-glucose derivative that has a fluorescent chromophore in the molecule with different cells in the same cell strain to be evaluated, respectively, comparing the fluorescence emitted by the D-glucose derivative that has a fluorescent chromophore in the molecule and is specifically incorporated into cells with the fluorescence emitted by the L-glucose derivative that has a fluorescent chromophore in the molecule, and evaluating the specific incorporation of D-glucose into cells relative to L-glucose by taking the difference between the two kinds of fluorescence intensities.
|METHOD FOR DETECTING HEPATIC INJURY DUE TO ANTITHYROID DRUG - The present invention relates a detecting method of distinguishing a temporary liver function test abnormalities by a thyrotoxicosis from a drug-induced hepatic injury by an antithyroid drug using a blood test and the likes, which is performed in a simple manner and with specificity. In the course of treating Graves' disease using an antithyroid drug, it is possible to differentiate a temporary liver function test abnormalities resulted from a thyrotoxicosis from a drug-induced hepatic injury resulted from the antithyroid drug, and therefore to detect the drug-induced hepatic injury with specificity by assaying a level of OCT in a body sample from a patient. In other words, it is possible to diagnose as a drug-induced hepatic injury if a blood OCT level in the sample from the patient is elevated compared to a level prior to administering the antithyroid drug or a blood OCT level from normal persons. Meanwhile, if the OCT level is not changed in spite of elevated levels of transaminases in the sample, it is possible to continue the treatment without discontinuing the drug administration since liver function test abnormalities in this case can be judged as temporary abnormalities owing to metabolic alteration, not as a drug-induced hepatic injury.
|TREATMENT OF POMPE DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARkERS - Provided is a method of monitoring the treatment of Pompe disease with specific pharmacological chaperones using systemic and/or cellular surrogate markers.
|PAAD DOMAIN-CONTAINING POLYPEPTIDES, ENCODING NUCLEIC ACIDS, AND METHODS OF USE - The invention provides isolated nucleic acid molecules encoding PAAD-domain containing polypeptides and functional fragments thereof, including fragments containing PAAD domains, NACHT domains and ARED domains, encoded polypeptides, and antibodies. Also provided are methods of identifying polypeptides and agents that associate with a PAAD-domain containing polypeptide or fragment thereof, or that alter an association of a PAAD domain-containing polypeptides. Further provided are methods of identifying agents that modulate PAAD domain-mediated inhibition of NFκB activity, or modulate an activity of a NACHT domain of a PAAD domain-containing polypeptide. Also provided are methods of modulating NFκB transcriptional activity in a cell, and methods of altering expression of a PAAD domain-containing polypeptide in a cell.
|METHODS FOR ASSAYING PERCENTAGE OF GLYCATED HEMOGLOBIN - The invention provides enzymatic methods for direct determination of percentage of glycated hemoglobin in blood samples without the need of a separated measurement of total hemoglobin content in blood samples. The methods utilizes one or two different types of oxidizing agents which selectively oxidize low-molecular weight reducing substances and high-molecular weight (mainly hemoglobin) reducing substances in blood samples, coupled with enzymatic reactions catalyzed by proteases, fructosyl amino acid oxidase, and peroxidase. The invention provides kits for performing the methods of the invention.
|Device for the Preparation and Fractioned Dispensing of Fluid Samples, Dispensing System Including Such Device and Related Method - The present invention relates to a device, to a system, and to a method for the preparation and fractioned dispensing of samples of a fluid. The device of the invention comprises a body having formed therein guide means suitable for receiving a sample-taker member and for guiding it in translation through the device, and at least one preparation chamber enabling an aliquot of a fluid sample dispensed into the chamber by a said sample-taker member to be prepared in a stream of a suitable reagent. The guide means pass through the preparation chamber and communicate therewith to enable an aliquot of fluid to be dispensed into the chamber in a determined position of the sample-taker member in the guide means. The preparation chamber has an introduction orifice for introducing at least one reagent into the chamber for mixing the reagent with an aliquot, and at least one dispensing orifice for dispensing the mixture formed by said aliquot and said reagent to recovery and/or analysis means.
|MICROFLUIDIC CELL SORTER AND METHOD - A biological particle sorting device and method of its use. The device includes structure arranged to urge biological particles into substantially single file travel through an interrogation zone. Operable alignment structure nonexclusively include sheathed fluid flow, capillary tubes, an orifice, and fluid microchannels. One or more detector, selected from a plurality of operable such structures, may be employed to sense the presence of a biologic particle in the interrogation zone. Certain exemplary detectors may operate on the Coulter principle, or may detect a Stokes' shift, or side-scatter radiation. Discrimination structure is generally provided to categorize particles as being in one or another sub-population of a mix of biological particles that may be carried in a fluid sample, such as by cell type, size, or the like. Killing structure, such as a laser, is disposed to neutralize all particles in any undesired sub-population while leaving undamaged the desired sub-population(s). The device may be operated to essentially purify (in a living or viable sense) a sample including biological particles that are carried in a fluid diluent.
|MEASURING MULTI-ANALYTE SAMPLES USING AN IN-LINE FLOW CELL - Methods and systems for analyzing ratios of analytes within a flowing sample are provided. The flowing sample can be processed in real-time to determine a time interval over which a predetermined amount of a group of analytes passes by a fixed point in a flow cell. The predetermined amount can be routed to a sample container for future processing. The sample can comprise diluted blood and the analytes can comprise a component of hemoglobin, such as A1c, and the total amount of hemoglobin, of which the predetermined amount is metered.
|METHOD FOR ANALYZING COLLAGENOUS TISSUES FOR THE DETECTION AND DIAGNOSIS OF BONE DISEASE - Methods and systems for diagnosing a bone disease related to collagen pathology in a subject are provided. These include providing a bone sample from the subject and determining a quantitative collagen morphology value of the bone sample. A reference value is provided from a non-affected control subject where the reference value is a quantitative collagen morphology value from the same type of bone sample obtained from a population of non-affected control subjects. The quantitative collagen morphology value of the subject's bone sample is compared to the reference value. If the collagen morphology value is altered versus the reference value, the subject is diagnosed as having a collagen related bone disease. The collagen morphology value can include mean fibril spacings and distributions of the fibril spacings taken from a subject's bone sample.
|MICROBIAL ENGINEERING FOR THE PRODUCTION OF CHEMICAL AND PHARMACEUTICAL PRODUCTS FROM THE ISOPRENOID PATHWAY - The invention relates to recombinant expression of a taxadiene synthase enzyme and a geranylgeranyl diphosphate synthase (GGPPS) enzyme in cells and the production of terpenoids.
|Systems And Methods For Segregating Mixed Material Streams - The invention relates to methods and systems of detecting useful material in a mixed solid, liquid and/or gaseous material stream. The methods include defining a value range requirement for at least one parameter of interest of useful material to be selected from the material stream, passing the material stream through at least one detector adapted to measure the parameter of interest of the material stream, and separating the material stream into useful material and residue based on the measured parameter. The systems comprise at least one detector adapted to measure a parameter of interest of the material stream passing therethrough; and at least one separator for separating the material stream into useful material and residue based on the measured parameter after passing through the detector. The system may further comprise treaters, processors, and controllers.
|METHODS OF GENERATING PATTERNED SOFT SUBSTRATES AND USES THEREOF - The present invention provides methods of generating and devices of patterned soft substrates, on which cells may be seeded, as well as methods of using these substrates. Devices containing these patterned soft substrates are also provided.
|AUTOMATED BIOLOGICAL SAMPLE COLLECTION SYSTEM AND METHOD - An automated biological sample collection system and method are disclosed. The system comprises an incubator, an applicator and a sampler. The incubator is configured to control the environment of a plurality of eggs, the applicator is configured to deliver exogenous material to the plurality of eggs and at least one sampler is configured to collect samples from the plurality of eggs, invasively or non-invasively.
|INTERACTIVE TRANSPARENT INDIVIDUAL CELLS BIOCHIP PROCESSOR - An Interactive Transparent Individual Cells Biochip Processor (ITICBP) device is described, which is useful for assessing a single, individual living cell at identifiable location or assessing group of cells each at identifiable location.
|METHOD FOR PREPARING CELL STANDARD - The present invention relates to a method for preparing cell samples for histological examination and, more particularly, a method for preparing a cell sample as a standard, or control, for use in the fields of cytology and histology.
|CELL DETECTION METHOD, AND MICROARRAY CHIP FOR USE IN THE METHOD - Disclosed is a detection method for detecting a specific cell in a sample containing multiple cells including the specific cell. Specifically disclosed is a detection method for detecting a specific cell in a sample containing multiple cells including the specific cell, which comprises the following steps (1) and (2): (1) retaining cells contained in the sample on a microarray chip which comprises multiple microchambers, wherein each of the microchambers can contain multiple cells; and (2) confirming the presence or absence of the specific cell in the cells retained on the microarray chip.
|System for testing biological and chemical agents using two or more cartridges simulating systems in the body - The present invention relates to joining two or more cartridges containing cell or tissue cultures from different organs found in the human body in fluid connection. It includes a vitro method and system for testing chemicals and agents as they pass through organs other than the brain or combinations of body systems including the brain. It greatly enhances the ability for researchers to test a proposed chemical or agent on human cells and tissue prior to testing it in vivo. Often, it is found that chemicals or agents have different reactions when tested on a single organ in vitro or in animals, than it does in the human body.
|Microbiological Analysis Assembly And Method - The assembly comprises a filtration unit (
|BIOSYNTHESIS OF DERIVATIVES OF MONACOLIN J - The invention relates to a process for obtaining monacolin J derivatives (I), wherein R
|METHOD FOR MODIFYING NON-STARCH CARBOHYDRATE MATERIAL USING PEROXIDASE ENZYME - A method for the modification of a material comprising a non-starch carbohydrate, which method comprises contacting said material comprising a non-starch carbohydrate with a polypeptide which has peroxidase activity and which is: a. a polypeptide comprising an amino acid sequence having at least 55% homology with an amino acid sequence set out in any one of: amino acids 21 to 513 of SEQ NO: 2; amino acids 20 to 510 of SEQ ID NO: 4; amino acids 1 to 493 of SEQ ID NO 6; or amino acids 1 to 491 of SEQ ID NO: 8 or b. a polypeptide encoded by a polynucleotide comprising the nucleotide sequence having at least 55% homology with a nucleotide sequence set out in any one of: nucleotides 61 to 1539 of SEQ ID NO: 1; nucleotides 58 to 1530 of SEQ ID NO: 3; nucleotides 1 to 1479 of SEQ ID NO: 5; or nucleotides 1 to 1473 of SEQ ID NO: 7.
|PENTOSE SUGAR FERMENTING CELL - The invention relates to a cell which comprises a nucleotide sequence encoding a xylose isomerase, wherein the amino acid sequence of the xylose isomerase has at least about 70% sequence identity to the amino acid sequence set out in SEQ ID NO: 3 and wherein the nucleotide sequence is heterologous to the host. A cell of the invention may be used in a process for producing a fermentation product, such as ethanol. Such a process may comprise fermenting a medium containing a source of xylose with a cell of the invention such that the cell ferments xylose to the fermentation product.
|NOVEL RECOMBINATION SEQUENCES - The present invention relates to novel nucleotide sequences, which are variants of att recombination sequences, involved in sequence-specific recombination of DNA in eukaryotic cells, whereby sequence specific recombination is performed by a bacteriophage lambda integrase Int. Such novel att recombination sequences being e.g. attP.b, attP.a, attL.a, attR.a and attR.b. The present invention further relates to a method of sequence-specific recombination of DNA in eukaryotic cells, comprising the introduction of a first DNA comprising a nucleotide sequence containing at least one recombination sequence into a cell, introducing a second DNA comprising a nucleotide sequence containing at least one further recombination sequence into a cell, and performing the sequence specific recombination by a bacteriophage lambda integrase Int, whereby at least one of said first or second DNAs is a novel att recombination sequences being e.g. attP.b, attP.a, attL.a, attR.a and attR.b.
|VIRAL NUCLEOCAPSID PROTEIN AS A MULTIFUNCTIONAL TRANSLATION INITIATION FACTOR AND INCREASED PROTEIN AND POLYPEPTIDE PRODUCTION USING SAME - The present invention is directed to a system to significantly increase the expression of genes of interest, and in particular proteins and polypeptide products. Expression of hantavirus nucleocapsid protein (N) by itself results in augmented translational expression of diverse genes. The mechanism of this augmentation relies on the ability of N to replace the cellular cap binding complex to attain more efficient translation initiation—the result being great mRNA production and greater protein/polypeptide production. The inventors have also recently found that inclusion of a 5′ untranslated leader region (viral UTR) from a viral RNA, in conjunction with N, leads to even more robust expression. This mechanism appears to involve recognition of the viral UTR by the N to provide even more robust protein production. Thus, a general strategy for expression of any gene would be to generate significant quantities of mRNA containing the viral UTR from a strong promoter, and then to allow translation of mRNA of a gene product in the presence of N. Even a modest increase in the production of commercially desirable proteins is a goal in industry.
|POLYNUCLEOTIDES ENCODING RECOMBINANT LUBRICIN MOLECULES AND USES THEREOF - Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided.
|Process for the Fermentative Production of Erythropoietin - The present invention relates to a process for the fermentative continuous production of erythropoietin, where eukaryotic erythropoietin-producing cells are cultured in a perfusion reactor while retaining the cells, the glucose concentration in the culture supernatant being adjusted via the perfusion rate and the cell number via the cell retention rate and/or the outward transferal of defined amounts of cell-containing culture medium from the bioreactor within preset zones.
|LOW CELL DENSITY FERMENTATION PROCESS FOR THE PRODUCTION OF HETEROLOGOUS RECOMBINANT PROTEINS IN MICROORGANISMS - A low cell density fermentation process for the production of heterologous proteins in microorganisms. The cell culture obtained by cultivating host microorganisms transformed with a vector carrying genetic material for the said proteins and an inducible promoter under batch fermentation conditions is fed with a feed medium after an OD
|NOVEL METHODS AND CELL LINES - This invention relates to fermentation processes for producing antibodies and other antigen binding compounds. Specifically, the present invention provides methods for increasing the specific productivity of an antibody produced in cell culture, increasing cell growth and increasing viability of cells in cell culture. Also provided are, expression stable, viable cell lines comprising DNA encoding adenovirus GAM1 and capable of producing a monoclonal antibody or fragment and/or variant thereof.
|Superagonistic Anti-CD28 Antibodies - The present invention relates to one or more nucleic acid(s) encoding a binding molecule specifically binding to a human CD28 molecule, comprising
|NOVEL HOT START NUCLEIC ACID AMPLIFICATION - Methods and compositions for performing nucleic acid duplication and amplification reactions are provided. A single-stranded nucleic acid binding protein is selected and provided in the reaction mixture which is assembled at a low, nonstringent temperature to include all of the necessary reagents for successful nucleic acid duplication or amplification reactions. By incorporating a single-stranded nucleic acid binding protein into the reaction mixture at low temperature, the generation of nonspecific products such as amplification products is improved despite the reaction mixture having been fully assembled at a nonstringent temperature.
|Methods for producing hyaluronan in a recombinant host cell - The present invention relates to methods for producing a hyaluronic acid, comprising: (a) cultivating a
|PROCESS FOR PRODUCING GLUTAMATE DERIVATIVES - The present invention relates to a process for producing efficiently glutamic acid derivatives (including salts thereof) such as monatin by converting a substituted α-keto acid of formula (1) into a glutamic acid derivative of formula (2) in the presence of an enzyme catalyzing conversion of the same.
|ESCHERICHIA COLI STRAIN WITH ENHANCED L-THREONINE PRODUCTIVITY AND METHOD OF PRODUCING L-THREONINE USING THE SAME - An L-threonine-producing
|CATALYST FOR THE DECOMPOSITION OF LIGNIN, METHOD FOR THE PREPARATION OF ALCOHOLS AND ORGANIC ACIDS, METHOD FOR THE PREPARATION OF LIGNIN-DECOMPOSITION PRODUCTS, CATALYST FOR THE DECOMPOSITION OF AROMATIC HYDROCARBONS, METHOD FOR RELEASING HYDROGEN IONS, AS WELL AS PORPHYRIN - Herein provided are a lignin-decomposition catalyst and an aromatic hydrocarbon-decomposition catalyst, which contain a porphyrin. Alcohols and organic acids can be isolated or separated from lignin by adding a solution containing an alkaline compound to lignin, optionally acting a lignin-decomposition catalyst on the resulting lignin-alkaline compound-containing solution and optionally irradiating, with light rays, the solution; or by optionally acting a lignin-decomposition catalyst on lignin and then irradiating it with light rays. The decomposition products generated during the isolation of the foregoing alcohols and organic acids are recovered and hydrogen ions are released from lignin. Herein provided also include a porphyrin having such a catalytic function that it can convert lignin into alcohols and organic acids; a porphyrin having such a catalytic function that it can decompose a compound containing an aromatic hydrocarbon in which an oxygen is linked to a carbon atom constituting the benzene ring thereof; and a porphyrin obtained by cultivating
|PROCESS AND APPARATUS FOR EXTRACTING BIODIESEL FROM ALGAE - The present invention relates to a system for cultivation of algae, extraction of lipids and transesterification of the lipids to obtain biodiesel. The system comprises three sections, that is to say cultivation, extraction and storage and reaction. In the lipid extraction area there is an ultrasonic reactor wherein the external walls of the alga are ruptured together with those of the oil sac to permit the extraction of lipids in the transesterification area there is also an ultrasonic reactor which ruptures the molecules of the fluid which passes therethrough to accelerate the reaction and render it almost immediate.
|METHOD FOR THE PRODUCTION OF FREE CARBOXYLIC ACIDS - A process for the preparation of free carboxylic acids including: A) preparation of carboxylic acid by a biological cell located in an aqueous medium with addition of an amine of formula (I)
|MICROBIAL SYSTEMS FOR PRODUCING COMMODITY CHEMICALS - Provided are improved recombinant microorganisms, and methods of use thereof, for metabolizing biomolecules and producing commodity chemicals such as ethanol therefrom, and genetic constructs to achieve that end.
|Construction of Protrophic/Celluloytic Yeast Strains Expressing Tethered and Secreted Cellulases - The present invention is directed to the construction of prototrophic, cellulo lytic strains of
|PRODUCTION OF BIODIESEL, CELLULOSIC SUGARS, AND PEPTIDES FROM THE SIMULTANEOUS ESTERIFICATION AND ALCOHOLYSIS/HYDROLYSIS OF MATERIALS WITH OIL-CONTAINING SUBSTITUENTS INCLUDING PHOSPHOLIPIDS AND CELLULOSIC AND PEPTIDIC CONTENT - The present invention relates to a method for producing fatty acid alkyl esters as well as cellulosic simplified sugars, shortened protein polymers, amino acids, or combination thereof resulting from the simultaneous esterification and hydrolysis, alcoholysis, or both of algae and other oil containing materials containing phospholipids, free fatty acids (FFA), glycerides, or combination thereof as well as polysaccharides, cellulose, hemicellulose, lignocellulose, protein polymers, or combination thereof in the presence of an alcohol and an optional acid catalyst.
|Utilizing Waste Tail Gas From A Separation Unit Biogas Upgrade Systems As Beneficial Fuel - The invention relates to a method for utilizing low-quality tail gas derived from a pressure swing adsorption system or membrane system, which is used to upgrade biogas, as a beneficial fuel for the facility and/or digester boiler.
|PROCESS FOR PRODUCING SILAGE FOR BIOGAS PRODUCTION - The invention provides the use of a lactic acid bacterium and optionally a
|ULTRASOUND ENHANCED GROWTH OF MICROORGANISMS. - A method of increasing the rate of growth, useful product production, or protein expression of a microorganism includes the step of exposing the microorganism to ultrasound having a frequency greater than about 1 MHz.
|TRAPPING, RECYCLING, AND OTHER TECHNIQUES INVOLVING CATALYSTS - Trapping, recycling, and other techniques involving catalysts are provided by this invention. The present invention provides for the retention of catalysts and other immobilized entities within a reaction region. In one aspect, the invention promotes such retention by incorporating support material regions including relatively little (or, in some cases, substantially no) catalyst (and thus, a relatively large number of catalyst adsorption sites) which can trap catalyst as it is transported through the downstream support material. In some cases, such arrangements can be achieved by using multiple beds arranged in series. In other instances, the amount of catalyst can be varied within a single bed to achieve the desired effect. The embodiments described herein can be used in systems in which the catalyst is covalently or non-covalently associated with the support surface.
|Carbonic Anhydrase Enhanced Reaction Methods and Formulations - Disclosed is a formulation for the absorption of CO
|METHODS AND COMPOSITIONS COMPRISING HEAT SHOCK PROTEINS - Compositions, and uses thereof, which are beneficial for eukaryotic cells in culture, and methods for their use in promoting cell growth, viability and recombinant protein expression. The methods disclosed in the present application are useful, for example, for improving cell viability and in accelerating the rate of cell growth of cells grown in culture. In one aspect, the supplements of the invention are useful for improving or enhancing the yield of the recombinant proteins from the cell cultures.
|COMPLEX - A complex comprising at least one target protein and at least one binding molecule having a binding affinity for said target protein, wherein said molecule having a binding affinity is covalently or non-covalently bound to at least one water-soluble polymer
|Intracellular Production of a Nuclease - Methods and compositions are provided that relate to obtaining a recombinant DNA and RNA cleaving nuclease. This involves the over-expression of a fusion protein between maltose-binding protein and a truncated nuclease in a soluble form in the cytoplasm of a host cell from which it can be readily extracted.
|FUSION PROTEIN COMPRISING AN E. COLI CHAPERONE PROTEIN AND A HUMAN CHAPERONE PROTEIN - The invention discloses the cloning, expression and uses of a chimeric fusion protein with superior chaperone and folding activities compared to the wild type chaperones. This invention relates to a chimeric fusion protein encoded by a recombinant DNA molecule containing nucleotide sequences coding for a polypeptide binding segment of a non-human chaperone protein and nucleotide sequences coding for an FK506 binding protein (FKBP) or an FK506-binding-protein-like domain (FKBP-like domain). In particular, this invention relates to a chimeric fusion protein encoded by a recombinant DNA molecule containing nucleotide sequences coding for a polypeptide binding segment of a non-human chaperone protein and nucleotide sequences coding for a human FKBP type peptidyl-prolyl-cis/trans isomerase (PPIase), methods of producing these chimeric fusion proteins and their uses as folding helpers in the production of other proteins and in the process of the production of vaccines or pharmaceuticals, and as folding helpers for performing immunoassays.
|METHOD FOR THE PRODUCTION OF AN ADDITIVE FOR THE ENZYMATIC DECOMPOSITION OF MYCOTOXINS, ADDITIVE, AND USE THEREOF - In a method for producing an additive for the enzymatic degradation of mycotoxins, in particular fumonisins, it is provided that at least one nucleic acid sequence of genes corresponding to sequences ID Nos. 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 is provided, the at least one nucleic acid sequence is expressed in prokaryotic or eukaryotic host cells, and at least one thus prepared enzyme corresponding to sequences ID Nos. 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25, or at least one complete recombinant host organism optionally along with a cosubstrate, are used in a vegetable raw material.
|Method and composition for crystallizing G protein-coupled receptors - Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion comprises the TM1, TM2, TM3, TM4 and TM5 regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, where the second portion comprises the TM6 and TM7 regions of the GPCR.
|TRANSFECTION VECTOR - The present invention relates to a novel secretory signal, a novel plasmid containing the secretory signal, a transformed anaerobic bacterium transformed with said plasmid, a gene transfer carrier consisting of said anaerobic bacterium, and a pharmaceutical composition containing said carrier.
|TRANSFECTION VECTOR - The present invention relates to a novel secretory signal, a novel plasmid containing the secretory signal, a transformed anaerobic bacterium transformed with said plasmid, a gene transfer carrier consisting of said anaerobic bacterium, and a pharmaceutical composition containing said carrier.
|METHOD AND DEVICE FOR THE DIGETSION OF BIOLOGICAL CELLS - The invention relates to a method and a device for the digestion of biological cells. Digestion of cells is understood as breaking up cells so that hereditary information can be removed. Using the present invention, nucleic acids are to be able to be removed from cells in particular. The nucleic acids include RNA and DNA. According to the invention, cells are digested in a vessel which can be connected to a line and can thus be part of an overall device. Liquid can drain out of the container or can be pumped into the container via the line, for example. The typical means for performing a mechanical digestion are located in the vessel, that is, in particular beads and a buffer solution. In contrast to the prior art, however, the vessel is not shaken, that is, subjected to vibrations. Instead, it is stirred with the aid of a magnetic stirrer. Strong vibrations are thus avoided. A vessel for performing digestion of cells can therefore be integrated without problems in an overall device.
|METHOD FOR PRODUCING LIPIDS - The present invention relates to a method for efficiently extracting and producing lipid components from crustaceans. A method for producing lipids, characterized by obtaining a squeezed liquid by squeezing a whole crustacean or a part thereof, heating the squeezed liquid to a temperature at which proteins contained in the squeezed liquid coagulate, carrying out solid-liquid separation so as to separate the heated squeezed liquid into a solid component that contains lipid components and an aqueous component that contains water-soluble components, washing the resulting solid containing lipids or a dried product thereof with water, dehydrating and/or drying, and then extracting lipids from the solid containing lipids or the dried product thereof.
|METHOD FOR PRODUCING CELL CULTURE SCAFFOLD - To provide a simple method for producing a cell culture scaffold material having a nanoporous surface in which the pore density, pore diameter and pore diameter distribution are easily controlled.
|ELECTROCHEMICAL SENSOR AND METHOD FOR MANUFACTURING - The present disclosure relates to a sensor including an elongated member including at least a portion that is electrically conductive. The elongated member includes a sensing layer adapted to react with a material desired to be sensed. An insulating layer surrounds the elongated member. The insulating layer defines at least one access opening for allowing the material desired to be sensed to enter an interior region defined between the elongated member and the insulating layer. The insulating layer has an inner transverse cross-sectional profile that is different from an outer transverse cross-sectional profile of the elongated member. The difference in transverse cross-sectional profiles between the elongated member and the insulating layer provides channels at the interior region defined between the insulating layer and the elongated member. The channels extend generally along the length of the elongated member and are sized to allow the material desired to be sensed to move along the length of the sensor.
|KIT AND METHOD FOR EVALUATING DETECTION PROPERTIES IN AMPLIFICATION REACTIONS - The invention relates to a kit comprising, (a) a first group of containers, comprising two or more containers with human genomic DNA, wherein the human genomic DNA in each of the two or more containers is of different human origin and the amount of DNA in the container is defined, (b) a second group of containers, comprising two or more containers with human genomic DNA, wherein the concentration of the DNA varies between the containers and the concentration of the DNA in the container is defined and (c) a third group of containers, comprising two or more containers with human genomic DNA, wherein the human genomic DNA in each container is a mixture of genomic DNA and is from at least two different individuals. The invention also relates to an evaluation tool and methods of use of the kit.


text:
'The Walking Dead' season 7 spoilers: Set photos reveal Carol may not return to Alexandria
Don't miss stories. Follow Raw Story!
Carol might embrace a new life with Ezekiel in The Kingdom after all. New set photos from The Walking Dead Season 7 might give us some clues about Carol's fate. [Warning: possible The Walking Dead Season 7 spoilers ahead] The Spoiling Dead Fans shared the leaked set photos on its official Facebook page. The images show…
By commenting, you agree to our terms of service and to abide by our commenting policy.

subset: commoncrawl


text:
Rogério Brito wrote: > > Only from a quick look, why orig.tar.gz contains only > > pp2p.jar? I suspect style files (and documentation or > > samples ?) could be also included. > > I received a feedback from Frank Küster on debian-mentors and I made some > improvements to the package already. > > The problem was that upstream didn't include a tarball. All he distributes > is the jar file, a wrapper shell script for calling the jar file (which I > adapted to meet things that I would think that would be reasonable in > Debian) and a bunch of style files. I also had to grab the manual > separately. Whoah. So there's no source code? Presumably your package is going in non-free then? The jar file distributed by upstream contains GPL code (GNU getopt) without source, so it probably isn't distributable even in non-free. However, according to the ppower4 web site: The post processing software is written in Java and it is free (refer to the GNU general public license). You might want to ask the author for the source since it's apparently GPLed. Cameron.
Description: Digital signature


text:
- Free delivery on orders over £30
- Premium Tracked £5.45 (Usually 2-3 working days)
- Economy £3.95 (Usually within 2-5 working days) Best Value
- Express Tracked £9.45 (1-2 Working days)
Snowman Window Christmas Sticker .Get in the Festive Mood and Brighten up your Windows with these Glitter Finish Stickers . Whether its the Home , Office , School or Shops !
Add a Review
Be the first to write a review about the Snowman Xmas Window Stickers 6 Styles A, Fancy Dress (Christmas)


text:
Scholarships On Offer from S J Jindal Trust
S J Jindal Trust invites applications for scholarships for economically weak but academically bright students from across India. The minimum marks required to avail of this scholarship is 65% in case of medical, engineering, MCA, diploma, BSc (Agri) and PG courses and 60% in case of graduates and others. Also, students getting 80% or more marks in PUC7 graduation will be considered for a 50% higher amount of scholarship. The scholarship will not be considered for profes¬sional courses such as LLB, LLM, ACA, AICWA, and ACS, among others. Moreover, donations are also being offered to charitable institutions engaged in the service of poor and disabled and those running schools and hospitals. Interested students and organisations can write to the Secretary, S J Jindal Trust, C-2, Green Park Extension, New Delhi-110016.
Comment for Scholarships On Offer from S J Jindal Trust
sir pleae also alert any agriculture officer post so soon alert
Dear Sir/Madam
I want to apply for the student scholarship.How should I apply?
i m studying mba in bangalore i am poor and cant able to pay the fees amount so can u plz help me to take scholarship from any source …..
Scholarships On Offer from S J Jindal Trust


text:
The Syria Files,
Files released: 1432389
The Syria Files
Thursday 5 July 2012, WikiLeaks began publishing the Syria Files – more than two million emails from Syrian political figures, ministries and associated companies, dating from August 2006 to March 2012. This extraordinary data set derives from 680 Syria-related entities or domain names, including those of the Ministries of Presidential Affairs, Foreign Affairs, Finance, Information, Transport and Culture. At this time Syria is undergoing a violent internal conflict that has killed between 6,000 and 15,000 people in the last 18 months. The Syria Files shine a light on the inner workings of the Syrian government and economy, but they also reveal how the West and Western companies say one thing and do another.
?H?O???????N??C?H??????N?v?C?????B?U??C?X?k?????q'????K?{'?~??17%?C?H?O??????N??CThu, 19 Nov 2009 19:21:48 +0300
|2009-11-19 18:22:48
??l?G?L?C?????B?U??C?X?k?????q'????K?{'?~??17%?C?A??q??G?????????????????????E???q?U??C?k???N?????CThu, 19 Nov 2009 14:13:48 -0200 ?X?k?????q'????K?{'?~??17% ?W?????A?s????? ????????N?? ?q??U?? ?????B?U?? ?G?L??U'???j???U?? ????~?? ?????I??~?? ??/
???~?????b???????z?~?? ??~?~??(OBU) ???????~?? ???~???????~?? ?w???q???:???????????????????? ?~?P?X???U??C?????B?U??C?X?k?????q'????K?{'?~??17%?C?g?a?U??C?G?L?T???U??CThu, 19 Nov 2009 15:13:48 -0100


text:
May 21, 2005
Anna walked down the shore from the changing house. She was holding the hem of her gown up with one hand, and a single calla lily in the other. The gown was a simple ivory sheath with spaghetti straps and random pearl accents. Her hair was down and her feet were bare. It was a bit blustery for May, but the sun was shining low in the sky. As she neared the small gathering of people, she had to laugh. Zach had done away with his tie, as she figured he would. What she didn't anticipate was that he had rolled up his trouser legs to mid calf. He was also barefoot. The touch of devil-may-care was one of many signs that Zach finally felt at peace with the world. He didn't have to hide behind a façade of suits and unreadable expressions. Anyone passing by could see that he was happy.
Now all that was needed was to pass his attitude on to his son. Ethan wasn't quite as ready to shed the formal aspect of his nature. He still had on his tie, and his shoes. Robin was wearing a midnight blue dress that fell to just below the knees. Her touch of whimsy was in a pair of flip flops that were also midnight blue, but were covered in sparkles. Anna smiled at Robin and Ethan. "Thank you for being our witnesses." Robin grinned impishly. "I finally get that brother I always wanted." Ethan's smile was stiff, but warm. "I can see already that I'm in for it."
Zach couldn't take his eyes off Anna. Her eyes were dancing, her smile never dimmed. She was finally happy again, and he couldn't believe that he was the one who made her that way. He saw her look up the beach, and then she turned to him with a mischievous grin. "Zach, I see that my wedding present is arriving." Zach gazed at her, letting her know without words that she was all he needed. But he obliged his future wife by looking in the direction that she pointed. His heart melted at the sight of Bianca and Maggie approaching. Bianca was holding Miranda in her arms. Anna stood next to Zach and leaned her head on his shoulder. "I know we decided to keep it simple – just Robin and Ethan – that way we wouldn't be tempted to invite more and more people until it got out of control. But how could we leave out Miranda? I just couldn't do it." Zach turned to face Anna, and lifted his hands to cradle the sides of her face. "Thank you." He kissed her for a long time, until the minister harrumphed. "I believe that is supposed to happen at the end of the ceremony."
Zach and Anna broke the kiss, laughing. The minister smiled and winked at them. He opened his little Bible and cleared his throat. As he spoke the words that began the time-honored tradition of the joining of two hands in holy matrimony, Zach and Anna faced each other, both of their hands clasped in the others'. They did not notice Maggie snapping pictures on her digital camera, or Ethan bouncing Miranda up and down, trying to distract her from her very clear desire to get down from his arms and toddle down the beach. They barely even noticed the sun beginning to set, and the lights of Monte Carlo starting to wink on as twilight came upon them. They only had eyes for each other.
As they held each other's gaze, they both thought back to that first day that they met, exactly five years ago. Both of their lives were covered in infinite darkness cast by shadows of the past. Together they found a ray of light in each other, but their past caught up with them, and enveloped them in darkness again. Now the past has firmly been put behind them. They chose sunset for their ceremony as a symbol. Because their love burns brightly, they will never fear darkness again.
Author's note: I chose May 21 to be a date of significance to Zach and Anna for the simple reason that it is my birthday. On the show, major events in their lives did happen around that date, so it seemed fitting. Most notably, Zach Slater appeared on All My Children on May 20, 2004. What a nice birthday present for me. The gift that keeps on giving.
For the first time in one of my fanfics, I am offering a chance to be drawn further into the story through a slide show I created. It contains screen caps of Zach and Anna (provided by and groups. and features the song presented in chapter 3 - Sweet Dreams by Air Supply. If you go to my profile, you can find the link.
I hope you enjoyed this story. It is my favorite, so far, of all the fanfic I've written. Thank you.


text:
PSG midfielder Yohan Cabaye has explained his decision to leave Newcastle United in January.
Cabaye declared the Premier League the best competition in the world.
"I really liked playing in another league and discovering another culture," Cabaye, a Ligue 1 winner with previous club Lille, told Uefa.com.
"Playing in the best league at the moment, it was a real discovery for me. I loved it, I enjoyed it a lot.
"The club, the supporters were great for me but when a club like Paris Saint-Germain wants you and does everything to have you, it's difficult not to accept it. It allows me to come and play to win titles like the French league, we're in the League Cup final and of course we're still in the race for the Champions League.
"For a football player, these are very important decisions to make. I didn't hesitate in coming here."
For breaking stories and all the great banter like us on Facebook: facebook.com/tribalfootball


text:
GRIT Referral Program
Many of you have been telling your friends, family, and random passers-by about the Freedom Chair – thanks! As a small company, happy customers are our most important asset. This is our way to give back and thank you for helping us spread the word.
How it works
- Enroll using the form linked below. You must be a current owner of a GRIT Freedom Chair or GRIT Freedom Chair Forward.
- We'll send you referral cards to make it easy to share.
- If you meet someone who's as excited about your GRIT Freedom Chair as you are, give them one of your cards.
- When they buy their own GRIT Freedom Chair they will get a special discount for sharing your name.
- 30 days after their purchase, we'll send you a referral bonus to thank you!
Referral Bonus Options
We've put together three great ways to thank you for helping us spread the word about the Freedom Chair. You'll be asked which bonus option you'd like when you enroll in the referral program, but you can change your selection at any time. Bonuses will be disbursed 30 days after a chair purchased with your unique referral code is delivered.
- Receive $200 cash (on a Visa gift card) for each Freedom Chair referred.
- Receive $400 credit towards a purchase in the GRIT Store (great for accessories and upgrades!)
- GRIT makes a $400 contribution to the GRIT Pay-it-Forward Low Income Fund on your behalf.


text:
CITY and Home Counties practice Penningtons is believed to be in talks over the future of one of its offices.
The firm will not confirm that it is holding the talks with partners from its Bournemouth office but a decision is expected to be reached this week.
The talks are thought to centre around the possibility of a demerger.
The eight-partner Bourne-mouth office, which became part of Penningtons after its merger with Ward Bowie in 1986, is home to the firm's renowned licensing practice. Licensing accounts for about 3.5 per cent of the firm's work. Bournemouth also handles planning and leisure-related work.
Penningtons managing partner David Stedman declines to confirm that any talks are under way. The Bournemouth partners have also refused to comment.


text:
About UCL
UCL was founded in 1826 to open up higher education in England to those who had been excluded from it – becoming the first university in England to admit women students on equal terms with men in 1878.
Academic excellence and research that addresses real-world problems inform our ethos to this day and are central to our 20-year strategy, UCL 2034.
A UCL education
UCL has the best academic to student ratio in the UK (1:10), enabling small class sizes and outstanding individual support (Times 2013).
- UCL is one of the top two universities in the UK for the number of professors, which means that our students are taught by the most highly qualified experts in their field (Higher Education Statistics Agency 2011).
- UCL provides an environment that encourages students to be ambitious yet idealistic. In 2013 alone, UCL students participated in 41,500 hours of voluntary work and set up 80 social enterprises and 25 student businesses.
Discover what makes a UCL education distinctive.
Our research
- UCL is the top-rated university in the UK for research strength. (REF2014)
- According to independent analysis, UCL won the largest funding allocation from the UK research councils in 2013 (£135m). UCL also has the greatest number of prestigious Doctoral Training Centres.
- UCL attracts the third highest number of academic citations per faculty member in the UK showing the high esteem and relevance of the institution's research. (QS 2013)
- All of UCL's research, subject to permissions, is placed in Discovery − UCL's online repository, available to everyone.
Find out more about our research.
Image (right): Zebrafish retina
Local and global impact
- Research conducted at UCL has profound benefits for society and the wider world. See examples of UCL research impact.
- UCL uses its expansive expertise to support start-ups and foster local businesses. To date it has helped strengthen more than 1,000 small businesses in London. Visit the UCL Enterprise website to see how we are helping to drive the global economy forward.
- See examples on the UCL and London website of how we share our resources and engage with the local community to enrich London's social, cultural and academic life.
Images: James Xu, Shine! 2011 International Student of the Year (upper left); Universities Minister David Willetts visiting UCL (lower left)
Discover the achievements of UCL staff and students thoughout our history.
UCL is based in the heart of London. Watch the video to learn more about our unique location.


text:
"Diablo's programs use movement activities and gymnastics basics to stimulate each child's sense of accomplishment and self-mastery. Every child should learn that learning is fun! Teachers actively foster self-esteem by accepting and encouraging our students. Through physical challenges, we create a series of "success opportunities." By the end of each lesson our chilren will have experienced many opportunities to say "I can do it!"
Our unique gymnastics education program encourages positive psychological development and provides cognitive stimulation that has been shown by the Department of Education to promote early intellectual growth. Children who participate in gymnastics and movement education classes develop sensorimotor skills that have been shown to improve both reading and math acquirement.
We can't overstate the value of the simple joy of running, tumbling, swinging, balancing, jumping, flipping, and cartwheeling through childhood! The physical confidence gained through gymnastics carries beautifully into every athletic activity your child may choose to pursue in adulthood."
Excerpted from the preschool's website


text: Module Name: pkgsrc Committed By: wiz Date: Fri Dec 12 22:05:56 UTC 2003 Modified Files: pkgsrc/devel/cvs: Makefile distinfo pkgsrc/devel/cvs/patches: patch-aa patch-ab patch-ac patch-ae patch-af patch-ah patch-al patch-am patch-an patch-ao patch-ap patch-aq patch-ar patch-at patch-au patch-av patch-az Log Message: Update to 1.11.10: Changes since 1.11.9: ********************* SERVER SECURITY ISSUES * Malformed module requests could cause the CVS server to attempt to create directories and possibly files at the root of the filesystem holding the CVS repository. Filesystem permissions usually prevent the creation of these misplaced directories, but nevertheless, the CVS server now rejects the malformed requests. GENERAL USER ISSUES * Case insensitive clients using a case sensitive server can now use a `cvs rm -f file; cvs add FILE' command sequence to add a file with the same name in a new case. * CVSROOTs which contain a symlink to a real repository should work. * The configure script now tests whether it is building CVS on a case insensitive file system. If it is, CVS assumes that all file systems on this platform will be case insensitive. This is useful for getting the case insensitivity flag set correctly when compiling on Mac OS X and under Cygwin on Windows. Autodetection can be overridden using the --disable-case-sensitivity and --enable-case-sensitivity arguments to configure. * A behavior change in `cvs up -jrev1 -jrev2' for modified files with a base revision of rev2 (ie, checked-out version matches rev2 and file has been modified). The operation is no longer ignored and instead is passed to diff3. This will potentially re-apply the diffs between the two revisions to a modified local file. Status messages like from a standard merge have also been added when the file would not or does not change due to this merge request ("[file] already contains the changes between [revisions]..."). * A bug which could stop `cvs admin -mTAG:message' from recursing has been fixed. * Misc documentation cleanup and fixes. * Some of the contrib scripts, some of the documentation, and sanity.sh were modified to use and recommend more portable commands rather than using and recommending commands which were not compatible with the POSIX 1003.1-2001 specification. DEVELOPER ISSUES * A new set of tests to test issues specific to case insensitive clients and servers has also been added. * Support has been added to the test suite to support testing over a :ext: link to another machine, subject to some stringent requirements. This support can be used, for instance, to test the operation of a case insensitive client against a case sensitive server. Please see the comments in TEST and the src/sanity.sh test script itself for more. * We've standardized on Automake 1.7.9 to get a bug fix. See the note below on the Autoconf upgrade for more details. * We've standardized on Autoconf version 2.58 to avoid a bug and get at a few new macros. Again, this should only really affect developers, though it is possible that CVS will now compile on a few new platforms. Please see the section of the INSTALL file about using the autotools if you are compiling CVS yourself. Changes from 1.11.8 to 1.11.9: * CVS now knows how to report, as well as record, `P' record types. * When running the `cvs history' command, clients will now send the long-accepted `-e' option, for all records, rather than explicitly requesting `P' record types, a request which servers prior to 1.11.7 will reject with a fatal error message. * A problem with locating files requested by case insensitive clients which was accidentally introduced in 1.11.6 as part of a fix for a data loss problem involving `cvs add's from case insensitive clients has been fixed. The relevant error message was `cvs [<command> aborted]: filE,v is ambiguous; could mean FILE,v or file,v'. * Attempts to use the global `-l' option, removed from both client and server as of version 1.11.6, will now elicit a warning rather than a fatal error from the server. Changes from 1.11.7 to 1.11.8: * A problem in the CVS getpass library that could cause passwords to echo on some systems has been fixed. Changes from 1.11.6 to 1.11.7: * A segfault that could occur in very rare cases where the stat of a file failed during a diff has been fixed. * Any user with write privleges to the CVSROOT/checkoutlist file could pass arbitrary format strings directly through to a printf function. This was probably bad and has been fixed. White space at the beginning of error strings in checkoutlist is now ignored properly. * In client/server mode, most messages from CVS now contain the actual command name rather than the generic "server". * A long-standing bug that prevented most client/server updates from being logged in the history file has been fixed. * Updates done via a patch ("P" status) are now logged in the history file by default and the corresponding "P" history record type is now documented. If you're setting the LogHistory option in your CVSROOT/config file, you may want to add "P" to the list of record types. * CVS now will always compile and its own getpass() function (originally from GNULIB) in favor of any system one that may exist. This avoids some problems with long passwords on some systems and updates us to POSIX.2 compliance, since getpass() was removed from the POSIX.2 specification. * A bug that allowed a write lock to be created in a directory despite there being existing read locks when using LockDir in CVSROOT/config has been fixed. * A bug with short patches (`rdiff -s') which caused rdiff to sometimes report differences that did not exist has been fixed. * Some minor corrections were made to the diff code to keep diff & rdiff from printing diff headers with empty change texts when two files have different revision numbers but the same content. * The global '-l' option, which suppressed history logging, has been removed from both client and server. To generate a diff of this commit: cvs rdiff -r1.68 -r1.69 pkgsrc/devel/cvs/Makefile cvs rdiff -r1.14 -r1.15 pkgsrc/devel/cvs/distinfo cvs rdiff -r1.7 -r1.8 pkgsrc/devel/cvs/patches/patch-aa \ pkgsrc/devel/cvs/patches/patch-af pkgsrc/devel/cvs/patches/patch-am \ pkgsrc/devel/cvs/patches/patch-at cvs rdiff -r1.8 -r1.9 pkgsrc/devel/cvs/patches/patch-ab \ pkgsrc/devel/cvs/patches/patch-av cvs rdiff -r1.6 -r1.7 pkgsrc/devel/cvs/patches/patch-ac cvs rdiff -r1.5 -r1.6 pkgsrc/devel/cvs/patches/patch-ae \ pkgsrc/devel/cvs/patches/patch-ah pkgsrc/devel/cvs/patches/patch-al \ pkgsrc/devel/cvs/patches/patch-ap pkgsrc/devel/cvs/patches/patch-au cvs rdiff -r1.4 -r1.5 pkgsrc/devel/cvs/patches/patch-an \ pkgsrc/devel/cvs/patches/patch-ao pkgsrc/devel/cvs/patches/patch-aq \ pkgsrc/devel/cvs/patches/patch-az cvs rdiff -r1.9 -r1.10 pkgsrc/devel/cvs/patches/patch-ar Please note that diffs are not public domain; they are subject to the copyright notices on the relevant files.


text:
Two of the top European contenders for the Breeders' Cup World Championships—Goldikova and Workforce—were among a group of international horses that arrived at Churchill Downs late Oct. 30.
Trained by Freddie Head for Wertheimer & Frere's Goldikova is seeking to become the first three-time winner of a Breeders' Cup race when she goes in the TVG Mile (gr. IT). Prince Khalid Abdullah's Workforce, winner of the Investec Derby (Eng-I) and Prix de l'Arc de Triomphe (Fr-I) for trainer Sir Michael Stoute, will run in the Emirates Airline Turf (gr. IT).
Another star on the international flight was Midday, also owned by Prince Khalid and trained by Stoute, who will defend her title in the Emirates Airline Filly & Mare Turf (gr. IT).
Others on the flight include: Behkabad (Turf), Dangerous Midge (Turf), Debussy (Turf), Dux Scholar (Juvenile Turf, gr. IIT), Flood Plain (Juvenile Fillies Turf, gr. IIT), Mantoba (Juvenile Turf), Paco Boy (Mile), Plumania (Turf or Filly & Mare Turf), Precision Break (Marathon, gr. III), Quiet Oasis (Juvenile Fillies Turf), Tale Untold (Juvenile Fillies Turf), Theyskens' Theory (Juvenile Fillies or Juvenile Fillies Turf) and Utley (Juvenile Turf).
All of the horses on the flight went immediately into quarantine and, if all goes well, could be released in time for training on Monday, Nov. 1.


text:
Grey hair preventing goalkeeper Frank Andoh from making progress
One of Ghana's best goalkeepers, Frank Andoh, who once played in the national U-17, 20 and 23 teams, says his grey hair is becoming a hindrance to his football career.
He said coaches and football administrators were unwilling to hire his services as they were often deluded by his grey hair which they considered to be a sign of old age.
Speaking to Graphic Sports at his Obuasi base, a very worried Andoh, who helped Inter Allies survive the Ghana top flight league, disclosed that his natural grey hair which was common in his family had been his great disadvantage as people taught he was too old to play football.
He said at 25 and now an experienced keeper, he had been rejected by coaches.
"We are five brothers and I am the second but we all have it, even my elder brother, who lives in Holland and all his children, who are at very tender ages, are all grey.
Coach Oti Akenten, who nurtured me at the Ashgold Academy, saw me developing grey at the time,†he revealed.
"Sometimes, supporters hoot at me, thinking I'm too old to be playing with kids and, in fact it got to a time I had to dye my hair but my wife kicked against it and even ended in a quarrel,†he stated.
CommentsThis article has 1 comment(s), give your comment
awass says:August 13, 2014 10:40 amdont b perturbed by ur detractors n juz keep on training....cuz no expatraite manager wil turn u off


text:
|Search Results (83 videos found)
|NASASciFiles - Winds
NASA Why? Files segment describing how atmospheric particles are transported over distance by wind.
Genre: Educational
Keywords: Jennifer Olson; CAVE; Cave Automated Virtual Environment; Wind Vector; Global Wind Pattern; Jet Stream; Particle Lifetime; Sulfur Dioxide; Water Vapor; Sulfuric Acid;
Duration: 00:03:19
Popularity (downloads): 1765
|Salton Honored - A SMART Celebration: Influence of SMART on IR Systems #3
David Evans talked about one of the latest commercial systems using the Vector Space model, which is the CLARIT system.
Genre: Lecture
Keywords: Information Retrieval; SMART; Cornell; 30 Years; Computer Science; David Evans; Influence; Commercial Systems; Natural Language; NLP; Vector Space; Vector Space Model; CLARIT
Duration: 00:21:33
Popularity (downloads): 1109
|NASASciFiles - Wind Direction
NASA Why? Files segment explaining how wind travels and how it carries smell.
Genre: Educational
Keywords: Craig Moeller; Weather Map; Air Pressure; Weather Station; Anemometer; Wind Vane;
Duration: 00:02:41
Popularity (downloads): 1209
|NASAKSN - Wind Tunnels
NASA Kids Science News segment explaining how wind tunnels work and what they do.
Genre: Educational
Keywords: NASA Kids Science News; Wind Tunnel; Airplane; Fan; Wind; Testing; Models; Scale; Aircraft; Race Cars; Spacecraft;
Duration: 00:00:58
Popularity (downloads): 3839
|NASADestinationTomorrow - DT4 - Wind Tunnels
NASA Destination Tomorrow Segment describing wind tunnels and how aircraft designers use them to understand airflow.
Genre: Educational
Keywords: NASA Destination Tomorrow; Simulator; Aircraft; Scale Model; Testing; Research; Wind Tunnel; Performance Characteristics; Airflow; Fan; Open Return Wind Tunnel; Closed Return Wind Tunnel; Difuser; Test Section; Water; Nitrogen; Helium; Gases;
Duration: 00:03:46
Popularity (downloads): 2101
|NASAConnect - TOAT - Drag Activity
NASA Connect Segment involving students in an activity to create a wind tunnel to test the effect of drag while emphasizing data analysis.
Genre: Educational
Keywords: NASA Connect; Student Activity; Drag; Shape; Mass; Wind Speed; Wind Tunnel;
Duration: 00:05:04
Popularity (downloads): 1802
|NASA Connect - SOF - Wind Tunnel Testing
NASA Connect segment explaining the process of modeling and testing model aircraft. The video features two experts who explain how wind tunnels work.
Genre: Educational
Keywords: NASA Connect; Wind Tunnels; Testing; Models; Data; Research; Scientists; Aircraft;
Duration: 00:01:22
Popularity (downloads): 3051
|NASAConnect - TOAT - Wind Tunnels
NASA Connect Segment explaining wind tunnels and how they are used as research tools. It also explores the SR-71 Blackbird and why it's used as an ideal research test plane....
Genre: Educational
Keywords: NASA Connect; Wind Tunnel; SR-71 Blackbird; Test Plane; Measuring Tools; Flow Visualization; Turbulence;
Duration: 00:02:35
Popularity (downloads): 2526
|NASASciFiles - The Design Process
NASA Sci Files segment exploring the design process and how wind tunnels are used in this process.
Genre: Educational
Keywords: NASA Sci Files; Testing; Design; Birds; Wings; Wind Tunnel; Scale Models; Micro Aerial Vehicle; Biologists; Iterate; Data Collection; Analyze;
Duration: 00:01:56
Popularity (downloads): 1432
|NASAConnect - PW - Ice and Aircraft
NASA Connect Segment that explains how meteorology, specifically icing, effects the ground operations of aircraft. Explores research being conducted to study the effects of icing by using refrigerated wind tunnels.
Genre: Educational
Keywords: NASA Connect; Meteorology; Aircraft; Wind Tunnels; Icing;
Duration: 00:03:32
Popularity (downloads): 1329


text:
Tell us about your painting & staining project! We'll match you with the best painting & staining contractors right away.
Top Painting & Staining Pros in Albany, California
JP Painting(4)1045 Cragmont Ave, Berkeley, CA
Hi. My name is Juan Vento, and I'm from Berkeley, CA. I have been painting houses with my Father professionally in the bay area for more than 20 years. We are licensed and have all the know-how and equipment to provide higher quality for a lower price. We offer interior and exterior painting services for your home or business. Call us today!Read MoreSee Full Profile
LU Construction(2)39899 Balentine Dr, Newark, CA
CA Home Remodeling, Renovations, Home Improvements and Construction Services by L U Construction. We have built our excellent reputation over the years by putting our hearts and passion into every project we take on. We treat every project as if we are working on our own homes. Perfection is the standard practice when we take on a project and complete satisfaction is what we expect and guarantee.Read MoreSee Full Profile
Altista LLCNo Reviews3015 San Pablo Avenio, Berkley, CA
Artisticrat Painting IncNo Reviews877 San Jose Ave, South Lake Tahoe, CA
We are based in South Lake Tahoe, providing painting and staining services around the area.Read MoreSee Full Profile
CKM PaintingNo Reviews2580 senter rd, san jose, CA
DR PaintingNo Reviews566 Moscow St., San Francisco , CA
Energy RemodelingNo Reviews197 Iron Wood Dr , Pleasnt Hill, CA
Everlast Construction,INCNo Reviews1941 Oak Park Blvd #70 Pleasant Hill, Pleasant Hill, CA
Today, companies must overcome increasing challenges to meet customer needs and create shareholder values. These challenges are not just due to more difficult economic times. They result from increased competitive pressures and complexities in delivering a quality product. Companies must offer differentiated products at competitive prices in an ever-shorter amount of time. They need an extended team and design partner that can be trusted to deliver quality solutions on time. We provide complete REMODELING services that meet all your hardware design needs. Our services range from system architecture to design to development to testing and to sustaining. We take pride in our technical capabilities to complete and customize any project no matter how complex the requirements may be. Moreover, we have the design methodologies to ensure consistent quality designs resulting in lower total cost of ownership for our clients. Everlast construction 3 step process Design Products and Materials Construction Techniques Why Green Home? Energy Efficiency Good Indoor Air Quality Non-Toxic, Sustainable and/or Recycled Materials Save Money on Your Energy and Water Bills Reduced Maintenance Costs Increased Home Value Healthier Living Spaces A Healthier Planet and Better Future for AllRead MoreSee Full Profile
Greenworks / ModificationNo Reviews3127 Washoe Way, Pleasanton, CA
HL PaintingNo Reviews1518 89th Avenue, Oakland, CA
Jacob's Custom PaintingNo Reviews16682 Liberty Street, San Leandro, CA
Momentum ConstructionNo Reviews1080 La Cienega Blvd., Los Angeles , CA
My Construction Group incNo Reviews5022 Lindley Ave., Encino, CA
My Construction Group is a leading home remodeling company, interested in making the best and most remarkable construction in California.Read MoreSee Full Profile
ORION REMODELINGNo Reviews773 East El Camino Real #1005, Sunnyvale , CA
If you're looking for the best in remodel and design, look no further than the professional team at Orion Remodeling. We are a full-service, Bay Area based home remodeling company with one fundamental goal: to turn your dream home into your reality on time and on budget. We Service Santa Clara, Alameda, San Mateo & Contra Costa Counties. Orion Remodeling is a family-owned and locally operated business that strives to deliver beautiful craftsmanship that endures for years to come. We are certified Bathroom & Kitchen Remodeling company and offer may other services such as Interior/Exterior Painting, Flooring, Concrete work and much more! If you'd like to meet with our general contractors for a consultation, give us a call today.Read MoreSee Full Profile
Selvin RodriguezNo Reviews413 Lincoln ave, Redwood City, CA
Trujillo's PaintingNo ReviewsUpon Request, El Sobrante, CA
Unique Painting ServicesNo Reviews17C Oliva Drive, Novato, CA
UNIQUE PAINTING SERVICES founder, Juan Hernandez, has been painting for 18 years. He and his team are experienced in beautifying your investment with a simple freshening up of your existing color scheme or transforming your "tired" space with smart and new colors! Our Company has set itself apart in the Marin, Solano, and Contra Costa County as a full service painting contractor by meeting your high standards for quality with exceptional customer service at a competitive price every time.Read MoreSee Full Profile
A & J Quality General Construction Services912 Main Avenue, Suite A, Richmond, CA
A & V ServicesPO Box 9542, San Rafael, CA
Atlantis Decorative Coatings7060 Cutting Boulevard, El Cerrito, CA
Get free estimates from local painting & staining contractors
Trending Projects
Exterior Painting or Staining (walls)
Average Project Cost: $4,126Albany, CA 08/17/2016
- What work needs to be done? Paint walls, Paint trim, Power wash walls, deck, floor, or fence
- What type of painting project is this? Exterior
- When was the property built? Before 1978
Top Reviewed Pros
JP Painting(4)
I found juan and his dad very enjoyable .they did a great job and were responsive to every detail I wanted done and they did not skimp on the paint and used oil based primer (the best)..........they were very fast and efficient..................steve & pegRead More


text: Genetic DiscriminationNeurology Now: July-August 2007 - Volume 3 - Issue 4 - p 12 doi: 10.1097/01.NNN.0000286022.57121.b0 Department: the Waiting Room: Neurology News Congress is on the verge of breaking a 12-year impasse over legislation that would ban the use of genetic information by employers and health insurers. On April 25, 2007, the Genetic Information Nondiscrimination Act (GINA) of 2007 was passed in the U.S. House of Representatives by a vote of 420-3. The Senate has yet to vote, but President Bush has endorsed the bill. The specter of genetic discrimination has haunted Americans since the beginnings of genetic testing more than 30 years ago, but the launch of the Human Genome Project in 1990 and the subsequent advances in testing have given those fears a human face. Take Rebecca Fisher, a former medical librarian living in Oakton, Va., who was diagnosed with aggressive breast cancer at 31. Because the disease runs in her family, Fisher pressed her daughter Katie to get tested before leaving for college. The test showed that Katie has the breast cancer gene. "After the doctors explained everything health-wise," Fisher says, "they summed up by saying, 'Don't ever be without a group insurance plan.' And that was a stunning realization." Proponents of GINA say that without legal protections, patients are less likely to get tests that could benefit their health and to participate in research that can lead to better treatments. Fear of genetic discrimination could impact research on many neurological disorders, such as Alzheimer's disease, Parkinson's disease, stroke, and Huntington's disease. "We can't look [potential study participants] in the eye and tell them their fears are unwarranted until we have effective federal legislation to prevent that," says Francis Collins, M.D., Ph.D, who directs the National Human Genome Research Institute. Figure For more information on the Genetic Information Nondiscrimination Act of 2007, go to genome.gov/24519851 or visit the Web site of the Library of Congress at thomas.loc.gov.Copyright © 2007, AAN Enterprises, Inc.